Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab Combined With Apatinib and Capecitabine for Patients With Advanced Biliary Tract Cancer: a Phase 2, Single-arm, Prospective Study.

NCT04720131 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.

NCT NCT04720131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04720131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab Combined With Apatinib and Capecitabine for Patients With Advanced Biliary Tract Cancer: a Phase 2, Single-arm, Prospective Study.
Lead sponsor
Beijing Friendship Hospital
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2021
Completion date
May 30, 2023
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-pd-1 therapy, biliary tract cancer, capecitabine, targeted molecular therapy